Afatinib (BIBW2992)

Catalog No.S1011

Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

Price Stock Quantity  
USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Afatinib (BIBW2992) Chemical Structure

Afatinib (BIBW2992) Chemical Structure
Molecular Weight: 485.94

Validation & Quality Control

Cited by 35 publications:

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

EGFR Inhibitors with Unique Features

  • Selective EGFR Inhibitor

    Erlotinib HCl (OSI-744) EGFR-selective, IC50=2 nM.

  • FDA-approved EGFR Inhibitor

    Lapatinib Approved by FDA for breast cancer.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

  • Classic EGFR Inhibitor

    WZ4002 Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area
  • Inhibition Profile
  • Afatinib (BIBW2992) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Targets EGFR (L858R) [1]
(Cell-free assay)
EGFR (wt) [1]
(Cell-free assay)
EGFR (L858R/T790M) [1]
(Cell-free assay)
HER2 [1]
(Cell-free assay)
IC50 0.4 nM 0.5 nM 10 nM 14 nM
In vitro BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HDLM-2MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHjV5ZNUUN3ME2wMlAxPTd{IN88US=>NUfweY9DW0GQR1XS
KASUMI-1NEHtR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTYV3JHUUN3ME2wMlAxQTFzIN88US=>NWDNVWZ2W0GQR1XS
HCC2218M3\lT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTBwMEC5PFch|ryPMWLTRW5ITVJ?
KARPAS-45NWfwR41lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXDTWM2OD1yLkCxOlcyKM7:TR?=M3ryS3NCVkeHUh?=
HSC-4MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTBwMEG3OFgh|ryPNEHRXIhUSU6JRWK=
CHL-1MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTBwMEG4N|kh|ryPMVXTRW5ITVJ?
KY821MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTBwMEKwOkDPxE1?NHPNb3VUSU6JRWK=
NCI-N87NWP6b5pFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPqcHJKSzVyPUCuNFI4PzNizszNMXrTRW5ITVJ?
DOKM4HTfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;hOnFKSzVyPUCuNFMyQTRizszNM4jYNnNCVkeHUh?=
DSH1MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILWW4FKSzVyPUCuNFM{OTRizszNNYnWeFlSW0GQR1XS
MDA-MB-175-VIIM{HxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTBwMEO0NVYh|ryPM1mwfXNCVkeHUh?=
NCI-H2170M1\tRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XtO2lEPTB;MD6wN|czQCEQvF2=MVrTRW5ITVJ?
BT-474MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{P2PWlEPTB;MD6wOFk5PiEQvF2=M3i4eHNCVkeHUh?=
EFO-27M{jVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTBwMEWxPFIh|ryPM2DyUHNCVkeHUh?=
NCI-H720MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTBwMEWzNlUh|ryPNYn3XYVqW0GQR1XS
PC-14NWC1R|lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTBwMEW2Olgh|ryPM4jCN3NCVkeHUh?=
EC-GI-10NIHTVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWn6OYI3UUN3ME2wMlA2QTF{IN88US=>MVTTRW5ITVJ?
KYSE-450MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PiWWlEPTB;MD6wOVk4QCEQvF2=NYD5Vo1LW0GQR1XS
BPH-1NYH5W5M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULWVVlwUUN3ME2wMlA2QTh6IN88US=>MVjTRW5ITVJ?
NCI-H292MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;5emtKSzVyPUCuNFYxQSEQvF2=MkWxV2FPT0WU
H9NWf2Z5V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LSd2lEPTB;MD6wO|E{OiEQvF2=NXzj[VJ{W0GQR1XS
NCI-H526NWTDdZVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIG2UJJKSzVyPUCuNFc5OjNizszNNF7vO4dUSU6JRWK=
NCI-H1623NWXH[lBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTBwMEiwNlUh|ryPMVjTRW5ITVJ?
KYSE-140NFq3cZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4WzZWlEPTB;MD6wPFM{KM7:TR?=MU\TRW5ITVJ?
Ca9-22NIDifFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvKTWM2OD1yLkC4N|U{KM7:TR?=M4fxe3NCVkeHUh?=
AU565NYPB[oZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjCc|RKSzVyPUCuNFg2ODRizszNNXzqPIlsW0GQR1XS
ZR-75-30M2XHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfOTmdLUUN3ME2wMlA6PTR3IN88US=>NIDIbZdUSU6JRWK=
NCI-H1770NVXtTmZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2[4TmlEPTB;MD6xNFI5KM7:TR?=MXPTRW5ITVJ?
LB2241-RCCNXjFeGFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXv2bHZUUUN3ME2wMlExQDh2IN88US=>M4jGVnNCVkeHUh?=
CAL-39NHLmcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUWxU4g4UUN3ME2wMlEyPzl{IN88US=>NYP0O3ZbW0GQR1XS
UACC-893NXTYT4lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M362bGlEPTB;MD6xNVg5PSEQvF2=MVfTRW5ITVJ?
LU-65M4fhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;aTWM2OD1yLkGyOlM{KM7:TR?=M2LHfXNCVkeHUh?=
HNM4Kybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLq[2J6UUN3ME2wMlE{ODd5IN88US=>NHr1[mpUSU6JRWK=
TI-73M1HTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHiTWM2OD1yLkG0O|E2KM7:TR?=MXfTRW5ITVJ?
KU812NH\2VHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLrTWM2OD1yLkG1OFU3KM7:TR?=NU\qd4NJW0GQR1XS
SW13M3rZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTBwMU[yNVYh|ryPNEnjZ3lUSU6JRWK=
BB30-HNCNUXaRVYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrmWohKSzVyPUCuNVY2PzZizszNM3;lSXNCVkeHUh?=
HSC-2M1jlNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTBwMU[4N|ch|ryPMVnTRW5ITVJ?
BV-173M4DJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{Loe2lEPTB;MD6xO|U6PiEQvF2=MX7TRW5ITVJ?
CAL-27NXXtRZNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTBwMUe2N|Yh|ryPNEO3e4RUSU6JRWK=
SBC-1MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTBwMUi5OVkh|ryPMW\TRW5ITVJ?
CAL-33MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvyXpdIUUN3ME2wMlIxOTh2IN88US=>MV7TRW5ITVJ?
NCI-H209NIHQbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fydGlEPTB;MD6yNFQ3KM7:TR?=NFm1RnlUSU6JRWK=
COR-L105NUjXXJBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELZb3ZKSzVyPUCuNlExQDRizszNM3nGeHNCVkeHUh?=
HSC-3MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPXTFg{UUN3ME2wMlIyOTl6IN88US=>MlnMV2FPT0WU
NCI-H69NH3GNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzKTWM2OD1yLkKxOFUyKM7:TR?=MXvTRW5ITVJ?
MOLT-13MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;nbVZKSzVyPUCuNlM6PzVizszNMWrTRW5ITVJ?
ML-2MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHW0dlJKSzVyPUCuNlQ5ODJizszNNETq[G5USU6JRWK=
IGROV-1Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTBwMkW5OVIh|ryPNUTOS3c1W0GQR1XS
TK10MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnjLTWM2OD1yLkK2O|M5KM7:TR?=MmPrV2FPT0WU
EoL-1-cellMlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTBwMk[4PVIh|ryPM{O3XHNCVkeHUh?=
HO-1-N-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTBwMke4OVMh|ryPMWXTRW5ITVJ?
BHYM1HR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPINJZ3UUN3ME2wMlI5PjV3IN88US=>MljRV2FPT0WU
LU-139NFT6NppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTBwM{C1NUDPxE1?NU[0bodMW0GQR1XS
23132-87NEWyW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTBwM{G5NlMh|ryPMl2zV2FPT0WU
ACHNMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXocmxKSzVyPUCuN|E6QTRizszNNXnCXYZDW0GQR1XS
DoTc2-4510M1fXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTBwM{KyNVkh|ryPMkmzV2FPT0WU
BB65-RCCMmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFu1XYpKSzVyPUCuN|Q2QTNizszNNI\wNYtUSU6JRWK=
HLENVXLWlJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vCNGlEPTB;MD6zOVA1PiEQvF2=M{L0[XNCVkeHUh?=
HCC1419MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTBwM{[0NFgh|ryPNX\aUmNZW0GQR1XS
A388NV;ZZm5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX24N4ZwUUN3ME2wMlM3QDV5IN88US=>MmDCV2FPT0WU
NUGC-3NYHl[pRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPsdWFqUUN3ME2wMlM5Ozd|IN88US=>NXH3ZlNHW0GQR1XS
KYSE-180MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPUfYRRUUN3ME2wMlM6ODh7IN88US=>MmnZV2FPT0WU
TE-6M3T2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkGwTWM2OD1yLkSwNlQ3KM7:TR?=NUXaOGd{W0GQR1XS
A498MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\iTWM2OD1yLkSwOlc1KM7:TR?=MkS2V2FPT0WU
NCI-H1648NF3GS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTRbWZyUUN3ME2wMlQ1OTh{IN88US=>M3PLb3NCVkeHUh?=
DU-145MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTBwNES4N|Mh|ryPMWLTRW5ITVJ?
CW-2MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTBwNE[5NVQh|ryPNF7CSpRUSU6JRWK=
A431M1e3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXYTWM2OD1yLkS4NlM{KM7:TR?=MkXyV2FPT0WU
SASMoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLpU5NtUUN3ME2wMlQ5Ozl6IN88US=>MXPTRW5ITVJ?
NCI-H2126MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1m3VGlEPTB;MD61NVkzPiEQvF2=NIfFcmNUSU6JRWK=
NCI-H358Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4Xtd2lEPTB;MD61N|IyKM7:TR?=M2TOZXNCVkeHUh?=
FADUMl36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDZT2dSUUN3ME2wMlU1PDB2IN88US=>NVW3Zlh{W0GQR1XS
ACNMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3y[YxZUUN3ME2wMlU2ODl2IN88US=>NWizRmI{W0GQR1XS
HCC70MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M372VmlEPTB;MD61O|Y3OSEQvF2=MXvTRW5ITVJ?
NCI-H1838NWnpW25oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTBwNkCyPVkh|ryPM120UXNCVkeHUh?=
CAL-54MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTBwNkG2NlEh|ryPMkTsV2FPT0WU
NCI-H1975NETyNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{L0W2lEPTB;MD62NVczQCEQvF2=M{LzO3NCVkeHUh?=
COR-L88M{C5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXUTWM2OD1yLk[0NVE{KM7:TR?=M4DDWXNCVkeHUh?=
CTV-1NGC3R4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDSO29KSzVyPUCuOlQ{QTJizszNMoPHV2FPT0WU
EW-18MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVv5eW81UUN3ME2wMlY5Pjl6IN88US=>MorRV2FPT0WU
HCC1806NWrhXI42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml35TWM2OD1yLk[5OlY3KM7:TR?=MmfDV2FPT0WU
HuP-T4MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXf2e3h[UUN3ME2wMlY6PzZizszNMYLTRW5ITVJ?
MDA-MB-361MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HsUmlEPTB;MD63NlY3OiEQvF2=MoDEV2FPT0WU
NCI-H1573NXPJcVFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2Hk[WlEPTB;MD63N|Y{KM7:TR?=MnjSV2FPT0WU
KU-19-19MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XpfmlEPTB;MD63O|Q3PCEQvF2=NFXrfW9USU6JRWK=
COLO-678NULj[FA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYSzdWNWUUN3ME2wMlgxQDN2IN88US=>M1XyRnNCVkeHUh?=
C-33-AMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2W2Z2lEPTB;MD64NVI6PyEQvF2=MWjTRW5ITVJ?
Calu-3M{HHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTBwOEG0N|Qh|ryPMoPRV2FPT0WU
AGSMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLnepBKSzVyPUCuPFM3PDhizszNNYKycVU2W0GQR1XS
SCC-25MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrXTWM2OD1yLki0NVcyKM7:TR?=M17hNnNCVkeHUh?=
JVM-2MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXrZVNDUUN3ME2wMlg5Ojl7IN88US=>NFLlUZZUSU6JRWK=
HCE-TM3nQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjtZmVLUUN3ME2wMlg5PDJ6IN88US=>MWrTRW5ITVJ?
ES4NHTSWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXpXllKSzVyPUCuPVc5OzZizszNNHTMeY1USU6JRWK=
EKVXM1rGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLVTWM2OD1zLkCxNFY1KM7:TR?=MlzqV2FPT0WU
D-542MGNW\wUFd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTFwMEGwOlQh|ryPMlzWV2FPT0WU
SW1116MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYeyO2t7UUN3ME2xMlAyOjh5IN88US=>M4XFRnNCVkeHUh?=
5637M33T[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvmbGJIUUN3ME2xMlAyPTFizszNNWnubFR2W0GQR1XS
HT-1376NHSxVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnqTWM2OD1zLkCxOVE{KM7:TR?=MX7TRW5ITVJ?
NB69NVrjV|c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXXTWM2OD1zLkCyPVQ2KM7:TR?=MkC0V2FPT0WU
YKG-1M1;ibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTFwMEW0NVkh|ryPMWjTRW5ITVJ?
EW-3M1rzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorwTWM2OD1zLkC3PFg{KM7:TR?=NUDDZZB1W0GQR1XS
GCIYNF7SSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4O3e2lEPTB;MT6wPFExPCEQvF2=NWLjfXlsW0GQR1XS
SK-MES-1NXLPSItNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXp[lF2UUN3ME2xMlEyPDh5IN88US=>M1TJWXNCVkeHUh?=
PANC-08-13NIPqNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrZXYNpUUN3ME2xMlE3PDF4IN88US=>MUjTRW5ITVJ?
SK-NEP-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTFwMUe1NVMh|ryPNFz0RXJUSU6JRWK=
SW954MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\UfIJCUUN3ME2xMlIxOjF2IN88US=>M{jiOnNCVkeHUh?=
NCI-SNU-5M3G1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vqeWlEPTB;MT6yN|kh|ryPNEXBT29USU6JRWK=
SW48M1rsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfPN402UUN3ME2xMlI2PDN{IN88US=>MXfTRW5ITVJ?
HT-3M1TCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDYXYdKSzVyPUGuNlg4PTNizszNNF\uPG5USU6JRWK=
ETK-1M3TsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrGTWM2OD1zLkO3OFU3KM7:TR?=MXPTRW5ITVJ?
SCC-15MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTFwM{m0OVEh|ryPNGfkZ25USU6JRWK=
DU-4475M2C2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrsNIpSUUN3ME2xMlQxOTJzIN88US=>MVXTRW5ITVJ?
NB5NYjxfWtYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHf4PYNKSzVyPUGuOFE{OTdizszNMmT2V2FPT0WU
CFPAC-1NXXEU|Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjjTWM2OD1zLkSyOFk{KM7:TR?=NImzbXlUSU6JRWK=
NCI-H630MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLlTnQ5UUN3ME2xMlQ2PTh{IN88US=>NYTNdG1lW0GQR1XS
NCI-H82MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTybIhKSzVyPUGuOVQxODZizszNM33NfnNCVkeHUh?=
ECC10MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrLUpNKSzVyPUGuOVU{PjlizszNMke3V2FPT0WU
K5MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LkS2lEPTB;MT61PFM2PyEQvF2=NGLYOW1USU6JRWK=
ME-180M1vMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTFwNkGwPVYh|ryPM2n2cXNCVkeHUh?=
KYSE-410NUfkS5JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTFwNkW2O|Ih|ryPMl31V2FPT0WU
G-401NGnTNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV:wb5hNUUN3ME2xMlY4PDF|IN88US=>M171[3NCVkeHUh?=
TGBC24TKBNF75VItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PndGlEPTB;MT62PFI{KM7:TR?=M4nFVnNCVkeHUh?=
Detroit562M3zwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XKW2lEPTB;MT63NFE2OiEQvF2=NFHLVYJUSU6JRWK=
OE19NEPNd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfZNXNKSzVyPUGuO|E2OTJizszNM3zKfnNCVkeHUh?=
CAKI-1NFTNXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rwbGlEPTB;MT63PFIyOSEQvF2=NEDWe5NUSU6JRWK=
TE-12Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTFwOEC0NVQh|ryPNVK0WllzW0GQR1XS
NCI-H1666MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfU[2hKSzVyPUGuPFA6PDhizszNM2WydXNCVkeHUh?=
TE-1Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfTfZhKSzVyPUGuPFE1PzVizszNNHvmfmxUSU6JRWK=
CAL-12TNHzMZ4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fBRWlEPTB;MT64PFk1PSEQvF2=NXryWVlpW0GQR1XS
TE-8NUHoVIw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTFwOUGzO|ch|ryPM1vGWXNCVkeHUh?=
KYSE-270MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PzT2lEPTB;Mj6wNlc{OiEQvF2=M2fnSHNCVkeHUh?=
GMS-10MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELqNWRKSzVyPUKuNFM2OTdizszNMYPTRW5ITVJ?
A2780MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHHS4I6UUN3ME2yMlA3Ojl2IN88US=>NVzJO|dpW0GQR1XS
OMC-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3yTWM2OD1{LkC4NVY6KM7:TR?=MmfBV2FPT0WU
LoVoMnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoT1TWM2OD1{LkGwO|k4KM7:TR?=M4PYV3NCVkeHUh?=
PANC-03-27NYDRSYh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3ZTWM2OD1{LkG2OlMyKM7:TR?=NVv0WZNTW0GQR1XS
MDA-MB-157MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoOwTWM2OD1{LkKxPFI5KM7:TR?=NUnle5l7W0GQR1XS
CaR-1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHq3U4RKSzVyPUKuNlgzQDFizszNMYrTRW5ITVJ?
769-PMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7VcWJKUUN3ME2yMlI6ODN5IN88US=>NFvFcG1USU6JRWK=
NB7MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHxZ3huUUN3ME2yMlI6Pjd4IN88US=>M4ToWXNCVkeHUh?=
MKN7NFPoenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTVTWM2OD1{LkO1N|M2KM7:TR?=MkLDV2FPT0WU
NCI-H1048NFfCeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzuO5ZOUUN3ME2yMlQ6OTV6IN88US=>NGLme3FUSU6JRWK=
RCM-1M1fJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHEbW5qUUN3ME2yMlUzQTN6IN88US=>M3rSSnNCVkeHUh?=
HT55MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTJwNUezPEDPxE1?NVq5fGY6W0GQR1XS
HCC1569NX;KSmU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTJwNUiyPVch|ryPMmK5V2FPT0WU
LXF-289Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3P4WGlEPTB;Mj62N|U3PSEQvF2=M1m3N3NCVkeHUh?=
OVCAR-3MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTJwNkexOlch|ryPM1HBcHNCVkeHUh?=
TE-10MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHZUHMyUUN3ME2yMlY5ODd6IN88US=>NGPKc4NUSU6JRWK=
SNU-C2BMke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrhSGtKSzVyPUKuOlg3OTZizszNMYXTRW5ITVJ?
LB1047-RCCNIDoR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlO2TWM2OD1{Lke0PFg5KM7:TR?=M4DWVHNCVkeHUh?=
SN12CNHjs[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnT2TWM2OD1{LkmxPVY1KM7:TR?=M{\adnNCVkeHUh?=
786-0MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIf5O4NKSzVyPUOuNFY1ODhizszNM3;ifnNCVkeHUh?=
HT-29NGLZS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTNwMEezNFkh|ryPNHPv[IdUSU6JRWK=
RPMI-7951NYPhTFNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTNwMEe1PUDPxE1?Ml3IV2FPT0WU
NBsusSRMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnDTWM2OD1|LkG4NlU1KM7:TR?=NHjmbYNUSU6JRWK=
NKM-1NXGzbWdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTFTWM2OD1|LkG4O|Q1KM7:TR?=NVfMT5FxW0GQR1XS
Capan-2NXnh[4JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3y2W2lEPTB;Mz60Olg4PSEQvF2=MVzTRW5ITVJ?
MKN1MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3mzemlEPTB;Mz60O|ExQCEQvF2=M4fBSnNCVkeHUh?=
OAW-42M2LSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlH3TWM2OD1|LkWwNFI3KM7:TR?=MVzTRW5ITVJ?
SKG-IIIaMlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV6zVmQ5UUN3ME2zMlUzOjN5IN88US=>M3j5ZnNCVkeHUh?=
no-11NEDjdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\iNVh{UUN3ME2zMlU{PTZ2IN88US=>NWLrbWFiW0GQR1XS
NYM{nQ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13QeWlEPTB;Mz61N|Y2PSEQvF2=MXLTRW5ITVJ?
HEC-1M1:4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTNwNUi5OUDPxE1?MmPQV2FPT0WU
NCI-H441NGXKbnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkC2TWM2OD1|LkW5PFQyKM7:TR?=NEn1XXFUSU6JRWK=
NCI-H2009M4XpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfjU|NKSzVyPUOuOlEzOTZizszNNW\P[HlRW0GQR1XS
T47DNGX1NJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPobYRKSzVyPUOuOlIzOTdizszNMkfWV2FPT0WU
SNU-449NYnvSXF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofvTWM2OD1|Lk[1PFI3KM7:TR?=MWfTRW5ITVJ?
NCI-SNU-1NIPqdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTNwNkm3N|Uh|ryPM2jTXXNCVkeHUh?=
BT-20MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDsPZhKSzVyPUOuOlk4QTVizszNM4HmW3NCVkeHUh?=
LS-123MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\l[HFPUUN3ME2zMlc1Ojh2IN88US=>NYfYUJZrW0GQR1XS
8305CMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3jTWM2OD1|Lke1PVEyKM7:TR?=MV\TRW5ITVJ?
OCUB-MMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37iPWlEPTB;Mz63OlE5PyEQvF2=MXLTRW5ITVJ?
KOSC-2NETadXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvNPIVlUUN3ME2zMlg{PDVzIN88US=>MoS0V2FPT0WU
NCI-H1693MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXB[XBKSzVyPUOuPFQyQDFizszNMUPTRW5ITVJ?
TE-9M1\uZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnRdI1KSzVyPUOuPFQ{QDJizszNMULTRW5ITVJ?
MV-4-11M3\2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXZUGhpUUN3ME2zMlg4QTl2IN88US=>MkfUV2FPT0WU
GAMGNGq4Vm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTVTWM2OD1|LkmxN|E1KM7:TR?=NFj6ZZRUSU6JRWK=
KNS-62NUX1NpBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXi1OHpLUUN3ME2zMlk1PzNzIN88US=>NX\nbI41W0GQR1XS
MC116NICxcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV64dmFTUUN3ME2zMlk2PDh7IN88US=>MmfvV2FPT0WU
647-VNXvC[|RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTNwOUi0OVIh|ryPMkf0V2FPT0WU
U-87-MGM3j5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTRwMUC0PFEh|ryPNV3xNGdHW0GQR1XS
RPMI-8226NG\oWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrQOWdLUUN3ME20MlEyPjNzIN88US=>MoDzV2FPT0WU
SW1417NHP5TlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonsTWM2OD12LkGyNVQ4KM7:TR?=NIHFc49USU6JRWK=
LAMA-84M2nm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rzfWlEPTB;ND6xO|AzKM7:TR?=MV7TRW5ITVJ?
LS-513MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHhOYk2UUN3ME20MlMyOjF5IN88US=>M{m0V3NCVkeHUh?=
KLENGXh[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGizWmtKSzVyPUSuOFA5OTlizszNNWLtTWNKW0GQR1XS
HCT-116Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXmRVVKSzVyPUSuOFExODdizszNMWrTRW5ITVJ?
EPLC-272HMnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmixTWM2OD12LkSxOVM{KM7:TR?=NGLmN2hUSU6JRWK=
KS-1NHj3UnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVv2Nm4zUUN3ME20MlUxQDh7IN88US=>MVzTRW5ITVJ?
HT-1197NEK4UoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zWRmlEPTB;ND61NlY3QSEQvF2=MVnTRW5ITVJ?
LCLC-97TM1NUeyTFdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHKTWM2OD12LkWzOlg3KM7:TR?=MWrTRW5ITVJ?
ES5MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTRwOEO3NlMh|ryPNFrhXW5USU6JRWK=
CTB-1MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTRwOES4PEDPxE1?MYDTRW5ITVJ?
HL-60NWHBVHl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUmxeIdyUUN3ME20Mlg3PjFzIN88US=>MWPTRW5ITVJ?
VM-CUB-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfHTWM2OD12Lki2PFE6KM7:TR?=NIHHUXFUSU6JRWK=
MEG-01M4DaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDJdoNCUUN3ME20Mlk6PDB|IN88US=>NWX0TY9SW0GQR1XS
KYSE-520MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXe1R|ZsUUN3ME21MlIxQDN7IN88US=>M1fHZnNCVkeHUh?=
HuO-3N1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTVwMkSwOFMh|ryPMkPrV2FPT0WU
SW620M{GwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTVwMkS5OlQh|ryPNVTwZYRpW0GQR1XS
U031NYj2UIppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLiTWM2OD13LkK1OFI1KM7:TR?=MX7TRW5ITVJ?
TE-5NWO4RmNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTlTWM2OD13LkSwPFUh|ryPMX3TRW5ITVJ?
NCI-H747Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1ric2lEPTB;NT60NlQ4OiEQvF2=NGHKeZhUSU6JRWK=
MG-63M1vRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTVwNEi3OlIh|ryPM2Htb3NCVkeHUh?=
HC-1M17qZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTYd3N5UUN3ME21MlUyQDN7IN88US=>NY\DbWliW0GQR1XS
HCC2998NYG4T2F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4TzfmlEPTB;NT61NlYyPSEQvF2=NHTQVlhUSU6JRWK=
NTERA-S-cl-D1NID4bWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkGyTWM2OD13LkW0OVM4KM7:TR?=NIfhbFZUSU6JRWK=
KINGS-1NYjER5hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\zSGlEPTB;NT62NFk1PCEQvF2=NFL2SGJUSU6JRWK=
D-423MGMmjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTHc5d6UUN3ME21MlYyPzB3IN88US=>NVX5c2MyW0GQR1XS
SW962NUT4ZVQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnP3TWM2OD13Lk[yNFMzKM7:TR?=M{jZV3NCVkeHUh?=
LOXIMVIM1nZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;5cGlEPTB;NT62N|g4OyEQvF2=MV7TRW5ITVJ?
LS-411NNWTwU45tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rEUGlEPTB;NT63PVQ1OSEQvF2=NWPMWlhHW0GQR1XS
NCI-H2291M2Hldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWj3O4tPUUN3ME21Mlk5QTR|IN88US=>MWnTRW5ITVJ?
A549MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTZwMUK1OVMh|ryPMYDTRW5ITVJ?
LS-1034NHjnSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3npV2lEPTB;Nj6yNFcxPiEQvF2=Mlu1V2FPT0WU
NB14MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnXPVd[UUN3ME22MlQ{QDN4IN88US=>MVvTRW5ITVJ?
NCI-H1299NWTMTpZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDMSm5KSzVyPU[uOlMyPzFizszNMmLkV2FPT0WU
BT-549M{\QSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTZwNk[4PFkh|ryPNUnDcopEW0GQR1XS
J-RT3-T3-5MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXncm1KSzVyPU[uPFY6KM7:TR?=NIDBbWhUSU6JRWK=
SW756MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTZwOUGxO|Yh|ryPMk\SV2FPT0WU
DJM-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTZwOUKwNVIh|ryPNEjNc4FUSU6JRWK=
GP5dNGf3T4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITLb|hKSzVyPU[uPVc{QTRizszNNXfiXXkxW0GQR1XS
MOLT-4MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTdwMEKxN|Uh|ryPM{naSHNCVkeHUh?=
NCI-H28MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHJU29yUUN3ME23MlE3PDB3IN88US=>MX3TRW5ITVJ?
MN-60NIDkV5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvOem9KSzVyPUeuNlgxQDlizszNNYrsc4ZbW0GQR1XS
RMG-IMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPmNllKSzVyPUeuN|kzQTZizszNM4jp[3NCVkeHUh?=
COLO-800NXnz[WxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTdwNEG0OFYh|ryPNX\5bWhEW0GQR1XS
DBNEnmc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVewToY1UUN3ME23MlYyODB3IN88US=>MX3TRW5ITVJ?
Ca-SkiMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzNTWM2OD15Lk[0NlU6KM7:TR?=MXfTRW5ITVJ?
HELM3\hOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnpSFlRUUN3ME23MlcyOjB|IN88US=>NFzuXnBUSU6JRWK=
NH-12MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTdwN{K4NFgh|ryPMmDSV2FPT0WU
LB373-MEL-DNYD1TlV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzCTWM2OD15Lke2O|cyKM7:TR?=M1v2cnNCVkeHUh?=
SW900MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTdwOEKxNlEh|ryPMYPTRW5ITVJ?
JVM-3NY\1UoZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzVTWM2OD15Lki5OVk6KM7:TR?=MoHQV2FPT0WU
OAW-28M{XzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37lR2lEPTB;Nz65OFU4QCEQvF2=MlfIV2FPT0WU
KURAMOCHIMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;neYdKSzVyPUeuPVQ5OTFizszNNHLQZY9USU6JRWK=
BE-13NGXSSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\ZUZZTUUN3ME23Mlk5OTF{IN88US=>NIf1R2ZUSU6JRWK=
VMRC-RCZNHTISVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLNdJlKSzVyPUiuNFE3QTdizszNMlPQV2FPT0WU
NCI-H727NIrGfW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfH[2k6UUN3ME24MlExPDJizszNMY\TRW5ITVJ?
SW1710NULrUpZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrqbFdKSzVyPUiuNVg2OTVizszNM3HGcXNCVkeHUh?=
D-502MGM3P5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\NdmlEPTB;OD6yPVI5OiEQvF2=NHvGfVZUSU6JRWK=
NCI-H1993NVjrNoZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRThwM{O2N|Eh|ryPM1XCeXNCVkeHUh?=
SCC-4M1zifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnyPJBKSzVyPUiuOFQxPTlizszNMWnTRW5ITVJ?
HAL-01NH;5R5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\5VpBKSzVyPUiuOVE6OSEQvF2=NEXRe4ZUSU6JRWK=
GT3TKBMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWKwW|M5UUN3ME24MlY4QTZ2IN88US=>M3LSVHNCVkeHUh?=
SK-OV-3NHL0bFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLFeWxKSzVyPUiuO|E{OjlizszNMmT3V2FPT0WU
COLO-829MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HTZmlEPTB;OD64NFk4PiEQvF2=MlnSV2FPT0WU
OCI-AML2NIHBPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jMeWlEPTB;OD65OVQ5OSEQvF2=Mki5V2FPT0WU
OS-RC-2MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17MNmlEPTB;OT6wNlE6KM7:TR?=MWTTRW5ITVJ?
BFTC-909MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULBOoNiUUN3ME25MlA3Pzl7IN88US=>MlrJV2FPT0WU
EW-11M13zPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPFfmdKSzVyPUmuNVc3PTNizszNMknWV2FPT0WU
HCE-4NWSxWIdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVf4enNXUUN3ME25MlIyPTV6IN88US=>NH;sOoxUSU6JRWK=
BALL-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDzfYpWUUN3ME25MlIyQTB5IN88US=>MVzTRW5ITVJ?
SF539MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoG4TWM2OD17LkKzOVYzKM7:TR?=MUPTRW5ITVJ?
CAMA-1M3Txb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;zfYlKSzVyPUmuNlgyOjhizszNMkHJV2FPT0WU
C32NGDnc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTlwM{OwOlQh|ryPMVTTRW5ITVJ?
NCI-H1703MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTlwM{SzO|Uh|ryPMUnTRW5ITVJ?
NCI-H1650MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fQemlEPTB;OT62NFk1PiEQvF2=MWDTRW5ITVJ?
NCI-H1563MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTlwN{[wN|Eh|ryPMkT4V2FPT0WU
CAL-85-1M2LlZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjrUGZKSzVyPUmuPFc{QDNizszNMYHTRW5ITVJ?
UM-UC-3MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLPdWVyUUN3ME25Mlk2ODNizszNMWPTRW5ITVJ?
BxPC-3MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrMc2NKSzVyPUGwMlA6PzJizszNMn;qV2FPT0WU
MHH-PREB-1M1nLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4[1b2lEPTB;MUCuNVk6QSEQvF2=MmTIV2FPT0WU
DELNUPQTVVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPMOm5KSzVyPUGwMlM6PDZizszNNWjz[XlQW0GQR1XS
HuCCT1MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrVOmtKSzVyPUGwMlYxOzNizszNM4TFUnNCVkeHUh?=
OVCAR-4M1TGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13mRWlEPTB;MUCuPFg{PSEQvF2=NXP1dHV7W0GQR1XS
CAL-72NIrPWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XwdWlEPTB;MUCuPVM6OSEQvF2=MmWxV2FPT0WU
HCC1954NVrHfIs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTFzLkC3OVQh|ryPNHXOcGpUSU6JRWK=
EFO-21NGDJW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXPTWM2OD1zMT6xNFQ2KM7:TR?=MnvKV2FPT0WU
FTC-133NFnwe5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHv2eVdKSzVyPUGxMlE1ODdizszNNFHlNphUSU6JRWK=
SK-MEL-24MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmH6TWM2OD1zMT6yN|Y3KM7:TR?=NFK3R5RUSU6JRWK=
UACC-62MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7pTWM2OD1zMT6yN|Y5KM7:TR?=M3vF[XNCVkeHUh?=
NCI-H650NXy3TIw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fy[2lEPTB;MUGuNlQyQCEQvF2=MV;TRW5ITVJ?
ALL-PONVz0UolJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTFzLkK1NVIh|ryPNGTnXpJUSU6JRWK=
T84NEfqXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPJTWM2OD1zMT6zPVA4KM7:TR?=NIXuVndUSU6JRWK=
IST-MEL1M{PJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDubXZKSzVyPUGxMlQ2PTlizszNMkezV2FPT0WU
SW626MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfBZYRKSzVyPUGxMlU4PTVizszNM3q5[XNCVkeHUh?=
RPMI-2650MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTFzLkW4PFUh|ryPMl\0V2FPT0WU
MC-IXCM4nO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWW4XIoxUUN3ME2xNU43PzJ6IN88US=>NEDTUpFUSU6JRWK=
HOP-62NGjHfFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTFzLk[3OlQh|ryPM{jpUnNCVkeHUh?=
NOS-1M3rGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjxTWM2OD1zMT63NVA6KM7:TR?=NYLMNllTW0GQR1XS
SW1573NYDiXItwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIO1VoNKSzVyPUGxMlczQTVizszNNEHyPWFUSU6JRWK=
WM-115MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;YenJKSzVyPUGxMlc2QDhizszNNVr5clVQW0GQR1XS
HuO9M1;aVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LqRmlEPTB;MUGuPFc4PCEQvF2=Mm\rV2FPT0WU
YAPCNHnSZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTFzLkmyOVkh|ryPNGPCPGpUSU6JRWK=
MDA-MB-453Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfQS2lKSzVyPUGxMlk2OTVizszNMW\TRW5ITVJ?
NCI-H596NIOzNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILhbndKSzVyPUGyMlA{PjlizszNMVjTRW5ITVJ?
A172NHHYN2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTVTWM2OD1zMj6wO|k5KM7:TR?=M2HKZnNCVkeHUh?=
RS4-11NGm0fm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jLR2lEPTB;MUKuNVczPSEQvF2=MWjTRW5ITVJ?
HCC1937M4Tacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHTdYZoUUN3ME2xNk44PTZ2IN88US=>MoPyV2FPT0WU
SW837MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnS[mdKSzVyPUGyMlkxOjhizszNNYDvOmllW0GQR1XS
NMC-G1NHLZdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLYTWM2OD1zMj65NlM1KM7:TR?=NIHU[pNUSU6JRWK=
PFSK-1MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTF|LkC2JO69VQ>?NIjoOolUSU6JRWK=
DBTRG-05MGMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLNPWE5UUN3ME2xN{4xPjN{IN88US=>MnHOV2FPT0WU
SK-UT-1NEmzfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nicmlEPTB;MUOuNVA5OyEQvF2=NXnG[HBbW0GQR1XS
OVCAR-5MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofqTWM2OD1zMz6xOVk{KM7:TR?=NHvoWotUSU6JRWK=
8505CMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTF|LkKwOlch|ryPNVu2b4F3W0GQR1XS
SK-MEL-1M1\YcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHVRYRKSzVyPUGzMlcyOzVizszNNWj6flduW0GQR1XS
LK-2M{fnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDxTWM2OD1zMz63OlM6KM7:TR?=NGP2ZY9USU6JRWK=
OE33NXnrTmROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHpNHFKSzVyPUGzMlc5PiEQvF2=M2DtfHNCVkeHUh?=
Ramos-2G6-4C10NWHBd4g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{C1NWlEPTB;MUSuNFIxOiEQvF2=NHLy[nJUSU6JRWK=
EW-13NGrZSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTF2LkCzOVIh|ryPNGDhdolUSU6JRWK=
NCI-H1793NEDCOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLiWJlKSzVyPUG0MlIxQDdizszNM3XmOXNCVkeHUh?=
BHT-101MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTF2LkK0NUDPxE1?M3WyfXNCVkeHUh?=
RKOMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jGd2lEPTB;MUSuOVA4PSEQvF2=NInCcoRUSU6JRWK=
NEC8MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTF2LkW0O|Ih|ryPNYPQbYtSW0GQR1XS
PANC-10-05M4m0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjpcmdjUUN3ME2xOE43OjR5IN88US=>MUnTRW5ITVJ?
NCI-H2030MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTF2Lk[0OFgh|ryPMYnTRW5ITVJ?
C2BBe1NEXLUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TidmlEPTB;MUSuO|Y1KM7:TR?=MVLTRW5ITVJ?
EM-2NHHIUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1u0UmlEPTB;MUSuPFU4PiEQvF2=M4jaNnNCVkeHUh?=
HCC1395NU\MUoJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTF2LkmzN|gh|ryPM1HvWHNCVkeHUh?=
A2058NInVTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TpbWlEPTB;MUWuNFQxQSEQvF2=M1i5WnNCVkeHUh?=
SW1463MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjUWoZxUUN3ME2xOU4xPDh3IN88US=>NV;leZdFW0GQR1XS
J82M2\FOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDYVlc6UUN3ME2xOU4xPTdizszNNG\kPJJUSU6JRWK=
CAL-120MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\MeFR{UUN3ME2xOU4yPDR5IN88US=>NIfrVIVUSU6JRWK=
COLO-824MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHwPGx7UUN3ME2xOU4yPTd7IN88US=>M4i3[XNCVkeHUh?=
LNCaP-Clone-FGCMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTF3LkSyOFgh|ryPNHq5TIxUSU6JRWK=
CP66-MELM37COWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlGzTWM2OD1zNT60Olg5KM7:TR?=MlvnV2FPT0WU
OC-314NWTaNWtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLrVXNKSzVyPUG1MlQ4OTRizszNMY\TRW5ITVJ?
OVCAR-8NHX4SmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTHXHZuUUN3ME2xOU45QDZzIN88US=>NHHIT2VUSU6JRWK=
MFE-280NF3HepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTF4LkC0PFgh|ryPMofPV2FPT0WU
MHH-NB-11NFf0TWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTF4LkC4N|kh|ryPMVfTRW5ITVJ?
SW1990NFzP[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfuemRKSzVyPUG2MlE4PTVizszNMnfXV2FPT0WU
U-266NVvsZXNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlf1TWM2OD1zNj6yNlk6KM7:TR?=NYD6UlNzW0GQR1XS
MFM-223NWn2cIROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHMT217UUN3ME2xOk4{QTZ3IN88US=>MULTRW5ITVJ?
L-363NXzsWIU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DVcWlEPTB;MU[uOFU4PyEQvF2=MVXTRW5ITVJ?
MCF7NUnzTVFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzvdo5KSzVyPUG2MlQ4OjNizszNMn\CV2FPT0WU
SK-MEL-3NWPBVmlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljITWM2OD1zNj60O|g4KM7:TR?=M4SyWXNCVkeHUh?=
HHNHf4S3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLl[VdKSzVyPUG2MlUyPjJizszNMYHTRW5ITVJ?
no-10NIPvWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrZbVgxUUN3ME2xOk43OzR|IN88US=>Ml7nV2FPT0WU
HuP-T3MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPab4tKSzVyPUG2MlY2PzZizszNMnm4V2FPT0WU
QIMR-WILNGTKUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvFb5lKSzVyPUG2MlcyODVizszNMkjkV2FPT0WU
NCI-H1092MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPXTWM2OD1zNj64N|E3KM7:TR?=M1WxeXNCVkeHUh?=
MZ2-MELM3yzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\rW4JKUUN3ME2xOk45PDB|IN88US=>MXHTRW5ITVJ?
ES3NFzHSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYDJR|UxRTF4LkmxN|Qh|ryPNIjTb3BUSU6JRWK=
COLO-684M2XPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfxTWM2OD1zNj65OFc4KM7:TR?=NWjpN3BXW0GQR1XS
NCI-H661MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlG4TWM2OD1zNj65Olk1KM7:TR?=MXLTRW5ITVJ?
CP50-MEL-BNIDSeWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TZSmlEPTB;MUeuNFM1OyEQvF2=NUCyb4ZRW0GQR1XS
NCI-H2405NWXz[5FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGG5cFlKSzVyPUG3MlE6PzRizszNNX;QOJU1W0GQR1XS
U-2-OSMlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTBTWM2OD1zNz61N|A4KM7:TR?=M1rEbnNCVkeHUh?=
RERF-LC-MSMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTIcmJ7UUN3ME2xO{42PTB6IN88US=>MXHTRW5ITVJ?
NCI-H2342NYDnXY45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4T6R2lEPTB;MUeuOVU4KM7:TR?=NXPXVnVTW0GQR1XS
ES8Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rVVGlEPTB;MUeuOlA5PyEQvF2=MYHTRW5ITVJ?
MOLT-16M{P5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnycpBWUUN3ME2xO{45QTN2IN88US=>NX[4NmF2W0GQR1XS
RH-18MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWftVGR5UUN3ME2xPE4xODN3IN88US=>MXjTRW5ITVJ?
D-283MEDNVT4RWQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVm4[YZsUUN3ME2xPE4xODh6IN88US=>M4nxT3NCVkeHUh?=
RCC10RGBM13XTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrrTWM2OD1zOD6wOVU6KM7:TR?=M3LJcXNCVkeHUh?=
NCI-H1437NIDSUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3TNGxDUUN3ME2xPE4yPjRzIN88US=>NV33W4NoW0GQR1XS
SW982MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPxTWM2OD1zOD6yOlcyKM7:TR?=NULvVWlLW0GQR1XS
IST-MES1M4KxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\XN45KSzVyPUG4MlQ1OjhizszNM13q[3NCVkeHUh?=
A704NWrYdFM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\6cnhIUUN3ME2xPE41PzV|IN88US=>MV7TRW5ITVJ?
ESS-1M1jHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\QS5dKSzVyPUG4MlUzODVizszNM3P1VHNCVkeHUh?=
SCHM1jYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zVfGlEPTB;MUiuOlQ2PiEQvF2=MlfCV2FPT0WU
COLO-320-HSRMnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGH1V4ZKSzVyPUG4Mlc1PiEQvF2=Mln1V2FPT0WU
Mo-TNXvGSI51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPBTWM2OD1zOD64NlA1KM7:TR?=MoTnV2FPT0WU
Saos-2MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHqOmdKSzVyPUG5MlEyPjJizszNNFX3fGFUSU6JRWK=
SW684NGDlcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVHYPIRbUUN3ME2xPU4yOzJ4IN88US=>M4jLOnNCVkeHUh?=
KMOE-2NVPqU2NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnj[VFKSzVyPUG5MlIzPDJizszNMlvtV2FPT0WU
MMAC-SFMn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2[zV2lEPTB;MUmuNlYxPyEQvF2=MUjTRW5ITVJ?
JARNW\Kfo5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTsNoRKSzVyPUG5MlI6QSEQvF2=MWTTRW5ITVJ?
SK-MEL-28MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTmdG9QUUN3ME2xPU4{OzZ|IN88US=>M1XBWnNCVkeHUh?=
KNS-81-FDM2\RWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUj2bHFjUUN3ME2xPU42PDZ6IN88US=>NETXcVdUSU6JRWK=
ES7MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTF7Lk[yPVIh|ryPNEDv[mlUSU6JRWK=
AsPC-1M2nTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7oTWM2OD1zOT62OFcyKM7:TR?=M4PzVHNCVkeHUh?=
NCI-H1155MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvUVYJKSzVyPUG5MlczOzhizszNMnXWV2FPT0WU
KYSE-510MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkmwTWM2OD1zOT64O|Q5KM7:TR?=MWfTRW5ITVJ?
ES1NVHENpdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXoTWM2OD1zOT65NlE{KM7:TR?=NVHVU|VkW0GQR1XS
PC-3M13IUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrEV2JKSzVyPUG5Mlk3ODRizszNNFrjbplUSU6JRWK=
GCTMkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXzTWM2OD1{MD6zNFI3KM7:TR?=NHj5[ZZUSU6JRWK=
KARPAS-299MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTJyLkO0NlIh|ryPMXzTRW5ITVJ?
DOHH-2NF3OdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTJyLkW0OlMh|ryPMVzTRW5ITVJ?
COLO-741MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2P5ZmlEPTB;MkCuOlYh|ryPMmjyV2FPT0WU
NCI-H1395NGPy[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoD2TWM2OD1{MD62Olk4KM7:TR?=M4\6eXNCVkeHUh?=
HCC1187NGniOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTJyLk[3N|Qh|ryPNF:3dIpUSU6JRWK=
BeckerNHfIclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTJyLkeyNFEh|ryPNIT3PItUSU6JRWK=
LU-134-ANHrRfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVHocGs{UUN3ME2yNU4yODJ4IN88US=>NEPaUZNUSU6JRWK=
MKN45M2DFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LNc2lEPTB;MkGuNVU2OSEQvF2=MmjHV2FPT0WU
LC-2-adM4X3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HlO2lEPTB;MkGuNlczQSEQvF2=MX;TRW5ITVJ?
EW-24MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmK0TWM2OD1{MT6zPVQ2KM7:TR?=NI\DVGdUSU6JRWK=
SK-N-ASMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DMVWlEPTB;MkGuPFI4PiEQvF2=M3rESnNCVkeHUh?=
NCI-H2052M17vWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfITWM2OD1{MT64PVY{KM7:TR?=Mn3BV2FPT0WU
A4-FukM3nOO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDvbZp5UUN3ME2yNk4yPDF7IN88US=>M2fPOnNCVkeHUh?=
NB10MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTHcZBKSzVyPUKyMlI{PzFizszNM1XYUHNCVkeHUh?=
CHP-212M2\4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDpTWM2OD1{Mj6zNlIzKM7:TR?=NGe4WHdUSU6JRWK=
KM12NVz2Zm1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzzO4JkUUN3ME2yNk4{PTZizszNNFL2TZBUSU6JRWK=
JEG-3M121UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fLNGlEPTB;MkKuN|c5KM7:TR?=Mk\rV2FPT0WU
LN-405MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXZcFB5UUN3ME2yNk42QTF|IN88US=>NX;vOXFTW0GQR1XS
HCT-15NV;KTWVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoC2TWM2OD1{Mj63OFQyKM7:TR?=Mne2V2FPT0WU
MLMANIH2doFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTJ{Lke0O{DPxE1?M2HadHNCVkeHUh?=
GI-1MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLSTWM2OD1{Mj63OlU5KM7:TR?=MoLaV2FPT0WU
RT-112MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnv1TWM2OD1{Mj64OlE3KM7:TR?=MYTTRW5ITVJ?
MPP-89MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\odWlEPTB;MkKuPFY3OSEQvF2=Moi1V2FPT0WU
A3-KAWNGnabHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvhTWM2OD1{Mz6xNFA{KM7:TR?=NGjr[ZhUSU6JRWK=
KALS-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTqXlM1UUN3ME2yN{4yPDF2IN88US=>MUXTRW5ITVJ?
SF126NITMTHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TYeGlEPTB;MkOuOlkzPCEQvF2=MkjiV2FPT0WU
SiHaMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTlTWM2OD1{Mz65N|I4KM7:TR?=M3rje3NCVkeHUh?=
MDA-MB-415MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLWTWM2OD1{Mz65OFk6KM7:TR?=Moq4V2FPT0WU
DaoyM{T4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXkTWM2OD1{ND6xNlYh|ryPMULTRW5ITVJ?
COR-L23MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDVNJAyUUN3ME2yOE4yPzZ5IN88US=>NU\jZnhMW0GQR1XS
KG-1NVfxeoc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTJ2LkG5Nlgh|ryPMUDTRW5ITVJ?
L-428M1S1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PCUWlEPTB;MkSuOVc6OSEQvF2=M{jqSXNCVkeHUh?=
NCI-H520MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW[0VYN6UUN3ME2yOE45QDZzIN88US=>MYfTRW5ITVJ?
COLO-792MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLBWXNKSzVyPUK1MlI4OzJizszNMXHTRW5ITVJ?
NB12MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWL4UXJrUUN3ME2yOU4zQTR5IN88US=>NHHiXFBUSU6JRWK=
GAKNF\1Um1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HOV2lEPTB;MkWuNlk3OyEQvF2=M13NWHNCVkeHUh?=
SW780M1PrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEToSWhKSzVyPUK1MlMzPjRizszNNV;VcW11W0GQR1XS
GB-1MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7SbHRKSzVyPUK1MlQxPjlizszNNFXWd5hUSU6JRWK=
P12-ICHIKAWANU\LZldKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTJ3LkS3PFUh|ryPNIHINFJUSU6JRWK=
NCI-H1651M{noOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PGV2lEPTB;MkWuOVk4KM7:TR?=MmPyV2FPT0WU
KE-37NELufo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnxTWM2OD1{NT63N|E2KM7:TR?=MYDTRW5ITVJ?
CCRF-CEMMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVS2bZNMUUN3ME2yOU46PjdizszNNXnVWohWW0GQR1XS
SF295NFfyNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;WTmlEPTB;Mk[uNFQzPSEQvF2=MWnTRW5ITVJ?
G-361NXyyS|hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vWfGlEPTB;Mk[uNVAzPyEQvF2=MoDGV2FPT0WU
HOP-92MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfaVmFKSzVyPUK2MlEzOjZizszNMkX4V2FPT0WU
UMC-11MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrUdXJKSzVyPUK2MlQ2OTRizszNNHzIc45USU6JRWK=
IST-SL1M3vpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDueY8{UUN3ME2yOk43PTlzIN88US=>Mnj4V2FPT0WU
TE-11NYDNdHFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzYTWM2OD1{Nj63O|UzKM7:TR?=M{fOT3NCVkeHUh?=
NCI-H1304M2LBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmOyTWM2OD1{Nj65NVA5KM7:TR?=MWTTRW5ITVJ?
SJSA-1MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHEXXRnUUN3ME2yO{4xOTd4IN88US=>MXrTRW5ITVJ?
BCPAPM2nlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlu1TWM2OD1{Nz6xN|ch|ryPNGq0S2ZUSU6JRWK=
HTC-C3NFW5XHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fj[mlEPTB;MkeuNlU3OSEQvF2=Mn71V2FPT0WU
EW-16MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoCwTWM2OD1{Nz6yPVQ4KM7:TR?=MXvTRW5ITVJ?
HT-144M1f1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTJ5LkSwN|Ih|ryPNXnrOHlGW0GQR1XS
MHH-ES-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LaUGlEPTB;MkeuOFQ1PyEQvF2=MVrTRW5ITVJ?
T98GNETRem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILjU3NKSzVyPUK3MlU5PDZizszNM2i4[HNCVkeHUh?=
RPMI-8866NGj4RYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUSzPG9XUUN3ME2yO{44PTZ{IN88US=>NUfOcFBkW0GQR1XS
BENNHv6N5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYP1eWltUUN3ME2yO{45PTF5IN88US=>NYjQOXg5W0GQR1XS
MDA-MB-231MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nHUmlEPTB;MkiuNlc6PSEQvF2=MXjTRW5ITVJ?
HuH-7MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HucmlEPTB;MkiuOFAzQCEQvF2=M{[5d3NCVkeHUh?=
SK-N-FINE\te|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTJ6LkSzN{DPxE1?MlOzV2FPT0WU
AN3-CAMn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fLV2lEPTB;MkiuOFM6PSEQvF2=NYTURpJXW0GQR1XS
EGI-1NFLNd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTJ6LkW5Nlgh|ryPMYDTRW5ITVJ?
697NGLvPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPkTWM2OD1{OD62N|MyKM7:TR?=M2XnUXNCVkeHUh?=
TCCSUPMoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HBbGlEPTB;MkiuOlQyQCEQvF2=M3;FN3NCVkeHUh?=
GR-STNGrCTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fmU2lEPTB;MkiuOlY6PiEQvF2=M320eXNCVkeHUh?=
SK-N-DZNITzNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYT4eFB1UUN3ME2yPE43QDh3IN88US=>NH7pZ|NUSU6JRWK=
MIA-PaCa-2MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTJ6Lke5OVkh|ryPNUDqUmVYW0GQR1XS
IGR-1MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nGc2lEPTB;MkiuPFg4PCEQvF2=NFHTem5USU6JRWK=
BFTC-905M3jYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DHVWlEPTB;MkmuNlcxPSEQvF2=MVPTRW5ITVJ?
NCI-H1581NX3sdYhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfIU4FEUUN3ME2yPU4{OTR3IN88US=>M{S4OHNCVkeHUh?=
RDM33TPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPu[m4zUUN3ME2yPU42OjN|IN88US=>MWTTRW5ITVJ?
SF268NVvXO3E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrr[JBKSzVyPUK5MlU6OzFizszNM13ncnNCVkeHUh?=
SHP-77NFzsS|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTJ7Lk[xPFIh|ryPMlXRV2FPT0WU
D-566MGNWOzTFIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTJ7LkmzPVMh|ryPMl3yV2FPT0WU
TGBC1TKBMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTNyLkGyN|gh|ryPMl;VV2FPT0WU
MEL-HOMn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfyToxKSzVyPUOwMlE1OjNizszNMXLTRW5ITVJ?
SJRH30MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTNyLkKxNFgh|ryPM4n5bnNCVkeHUh?=
D-336MGNXXLbVdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DJbGlEPTB;M{CuNlg6OiEQvF2=Mn7vV2FPT0WU
C3ANIPjeG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHXTWM2OD1|MD6yPVI4KM7:TR?=NV65SYk{W0GQR1XS
Calu-6Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTNyLkK5OlMh|ryPM1TlZnNCVkeHUh?=
MZ1-PCNWHzSZBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTNyLkO5N{DPxE1?M4PuTXNCVkeHUh?=
KYSE-70MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jhOGlEPTB;M{CuOVEyPCEQvF2=MmTSV2FPT0WU
CAPAN-1M2TncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUm0ZnlUUUN3ME2zNE42OThzIN88US=>NIHVSWZUSU6JRWK=
DK-MGMlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzvUHhKSzVyPUOwMlU1PTZizszNMkDUV2FPT0WU
SK-HEP-1NGfjU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTNyLk[zNlYh|ryPMUDTRW5ITVJ?
MS-1MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nH[2lEPTB;M{CuPFg5QSEQvF2=MX7TRW5ITVJ?
GI-ME-NNWrjbZR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXSz[3hQUUN3ME2zNU4xPTdzIN88US=>M4\4bnNCVkeHUh?=
NCI-H510AMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnX2TWM2OD1|MT60NFA3KM7:TR?=NIrYSnlUSU6JRWK=
NB17M3zrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTNzLkWxPFUh|ryPMYnTRW5ITVJ?
639-VNVKyUZBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTNzLkWyOFMh|ryPNFvLTINUSU6JRWK=
CAL-51NEL5TJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzyRVlbUUN3ME2zNU42PjZ5IN88US=>NGnQVFBUSU6JRWK=
HGC-27MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTNzLkW4O|Mh|ryPNYD3R|VIW0GQR1XS
GOTONUjEU2xlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XPcmlEPTB;M{GuPFUxPiEQvF2=NInlfoFUSU6JRWK=
ChaGo-K-1NXHGblJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TWSmlEPTB;M{KuNFA4KM7:TR?=MonnV2FPT0WU
RO82-W-1M{\HWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1X0O2lEPTB;M{KuNVYxPCEQvF2=MYTTRW5ITVJ?
SH-4NV;zVXd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGnIcWVKSzVyPUOyMlE5PThizszNNHLqW5JUSU6JRWK=
A204MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGT3c5BKSzVyPUOyMlUxPjlizszNMofxV2FPT0WU
DMS-273Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLsXINHUUN3ME2zNk42OzJ{IN88US=>MljRV2FPT0WU
KGNM3TQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTN{Lk[zN{DPxE1?MmLtV2FPT0WU
SK-MEL-2MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zUTWlEPTB;M{KuOlUzPyEQvF2=MUnTRW5ITVJ?
NCI-H2228MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF:1SZJKSzVyPUOyMlY3ODJizszNMYXTRW5ITVJ?
MKN28NEXueVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrKcVJKSzVyPUOyMlc5OzhizszNMV\TRW5ITVJ?
H-EMC-SSMnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvZTWM2OD1|Mj65Olc5KM7:TR?=NG\OXXlUSU6JRWK=
ATN-1M1zaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{OyfWlEPTB;M{OuNVQyPiEQvF2=NF3FNVBUSU6JRWK=
D-263MGMkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTN|LkizO|gh|ryPM1zZWXNCVkeHUh?=
LU-135NYPOW|JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYW1fWpFUUN3ME2zN{45QDJ7IN88US=>MoTNV2FPT0WU
C8166MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTN|Lki4OVQh|ryPNIm3PJdUSU6JRWK=
T-24M2fMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnNdGFMUUN3ME2zOE4xOjB3IN88US=>MWfTRW5ITVJ?
MewoM3HnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTN2LkGzOFkh|ryPMWDTRW5ITVJ?
22RV1NFH0S3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDDTWM2OD1|ND6xO|U1KM7:TR?=MVzTRW5ITVJ?
KM-H2M4H2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULJR29XUUN3ME2zOE4yPzd7IN88US=>NGjIXI9USU6JRWK=
NCI-H2122MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTN2LkO0O|Eh|ryPM1r0eHNCVkeHUh?=
ABC-1MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXXdYFNUUN3ME2zOE4{Pjl|IN88US=>M3PDT3NCVkeHUh?=
NCI-H1355MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoH0TWM2OD1|ND6zPFg6KM7:TR?=MXfTRW5ITVJ?
NOMO-1MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoL2TWM2OD1|ND61O|A{KM7:TR?=M2j2[nNCVkeHUh?=
MZ7-melNFLG[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTN2Lk[0PFch|ryPMkPLV2FPT0WU
NCI-H810NV;4TVN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITRToVKSzVyPUO0MlczPzhizszNMoDIV2FPT0WU
D-392MGNXLxbVdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLOTlZKSzVyPUO1MlA2PjVizszNNYi0Slg{W0GQR1XS
LB771-HNCNV;BR5RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTN3LkG2OVgh|ryPM1HqTHNCVkeHUh?=
COLO-679NEnPPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1i2UWlEPTB;M{WuN|g5KM7:TR?=NHTyVJBUSU6JRWK=
SK-PN-DWNFm2U41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\ITmlEPTB;M{WuOFM3QSEQvF2=NHvSUHdUSU6JRWK=
VA-ES-BJNV3qV3pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULpUVNiUUN3ME2zOU41PjR7IN88US=>NVrKcI5ZW0GQR1XS
KNS-42NUfKZllrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjLSpdkUUN3ME2zOU42QDJ4IN88US=>NGrRcpZUSU6JRWK=
RVH-421M2\6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfDOGNXUUN3ME2zOU44PjR3IN88US=>NVr0VIhtW0GQR1XS
P30-OHKMni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfHTWM2OD1|NT64O|UzKM7:TR?=MV7TRW5ITVJ?
G-402NF\Z[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnH4TWM2OD1|NT65PFY4KM7:TR?=Mon2V2FPT0WU
S-117MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYj4UG1{UUN3ME2zOk4{ODB6IN88US=>M{PqTHNCVkeHUh?=
RXF393MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHz1NmVKSzVyPUO2MlM4QDVizszNM1S5UHNCVkeHUh?=
LCLC-103HMl7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fSWGlEPTB;M{[uO|gxOyEQvF2=MmrTV2FPT0WU
U-118-MGNXzvXmJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTN4Lki4OFch|ryPMlLOV2FPT0WU
8-MG-BAM{XTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\YTWM2OD1|Nj65OFg{KM7:TR?=M4DGcnNCVkeHUh?=
MFH-inoMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTN5LkOzO|Eh|ryPNFTwcWFUSU6JRWK=
NCI-H23NFnKfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnZOXZKSzVyPUO3MlQyQTZizszNM3nzNXNCVkeHUh?=
NCI-H446M325cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHFTWM2OD1|Nz60PFYzKM7:TR?=MWnTRW5ITVJ?
LU-99AM{D1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnoSWJKSzVyPUO3MlU4OzFizszNNFjZVlJUSU6JRWK=
KP-N-YNNEnxc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjnTWZDUUN3ME2zO{43OTl3IN88US=>NGHye3lUSU6JRWK=
SCC-9M2G2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jXV2lEPTB;M{euO|g{QCEQvF2=NX3ieos3W0GQR1XS
EFM-19M2rPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTN5Lke5Olch|ryPNYPJRodTW0GQR1XS
A427MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4S4OGlEPTB;M{euPVExPyEQvF2=Mnz0V2FPT0WU
LB831-BLCM134RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTN6Lk[wN|kh|ryPM1PTcXNCVkeHUh?=
HOSM4rie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrpNY5EUUN3ME2zPU43Ojd|IN88US=>NX7j[YZ2W0GQR1XS
LAN-6NVyyPJd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWX3OpcxUUN3ME20NE4xOTF{IN88US=>MmHMV2FPT0WU
U251MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWewN5RRUUN3ME20NE41ODV2IN88US=>M2W0fnNCVkeHUh?=
SNU-387NULFe45WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHmTppHUUN3ME20NE41PTV|IN88US=>M3;X[3NCVkeHUh?=
DMS-79MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkK4TWM2OD12MD61PFg6KM7:TR?=M{XPUnNCVkeHUh?=
SK-LU-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1ywR2lEPTB;NECuOlU3QCEQvF2=MmHmV2FPT0WU
HTNX7lSoZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3VU3FUUUN3ME20NE43PjN7IN88US=>NVzVc2V{W0GQR1XS
KP-N-YSNFvWc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fzeWlEPTB;NECuOlc3QCEQvF2=NU\NN2hFW0GQR1XS
DMS-114M2LZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfYTWM2OD12MD64N|c1KM7:TR?=NUPrO4JWW0GQR1XS
HUTU-80NFuxdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTRzLkC1Olkh|ryPNUjWflhzW0GQR1XS
ONS-76M33kVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnS[o1KSzVyPUSxMlQ4ODlizszNNV22eXVsW0GQR1XS
A673MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XZO2lEPTB;NEGuOVE2PyEQvF2=MnvLV2FPT0WU
HPAF-IINInRSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\OVoVKSzVyPUSxMlY4ODlizszNNFvPO2RUSU6JRWK=
UACC-257M3ezPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3:1PGlEPTB;NEGuO|M3QSEQvF2=NHz0OJdUSU6JRWK=
EW-22MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFf4TppKSzVyPUSxMlg3QTdizszNMWPTRW5ITVJ?
NCI-H1755NIjSXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXSfnVKSzVyPUSxMlg4OjVizszNMm\ZV2FPT0WU
KYSE-150NVzT[IJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjzZpBRUUN3ME20Nk4yPzh{IN88US=>NWrJWnJbW0GQR1XS
CGTH-W-1NIP6bZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGq3TXZKSzVyPUSyMlQ6PTVizszNM1e5R3NCVkeHUh?=
NB13NU\VPHF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVX6UW5vUUN3ME20Nk43OjF5IN88US=>MUnTRW5ITVJ?
SW872MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTR{Lk[zN|Eh|ryPMknNV2FPT0WU
KP-4M4fvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTR{Lki4N|Ih|ryPNWC1SoIzW0GQR1XS
HCC38M4XVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrwTWM2OD12Mj65OlE5KM7:TR?=MUHTRW5ITVJ?
BB49-HNCNUXYenJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvVXm9uUUN3ME20N{4zOzV4IN88US=>M2Hrb3NCVkeHUh?=
CAL-62M37Mfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTR|LkSwNlgh|ryPNEnOeXFUSU6JRWK=
NCI-H2029NVzO[YpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTR|LkW1PFEh|ryPM4DpTXNCVkeHUh?=
M14NFLJVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTR2LkGzN|Ih|ryPM{nrOnNCVkeHUh?=
COLO-680NM4DvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXSyTm1sUUN3ME20OE4{OzlizszNNYf6cGQ4W0GQR1XS
Hs-578-TNGH3NHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTR3LkCyPVQh|ryPM1XOW3NCVkeHUh?=
MSTO-211HNWTTcodyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzvTms3UUN3ME20OU46PDh{IN88US=>MnXlV2FPT0WU
EW-1NYK4folxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVn1e2ZJUUN3ME20OU46Pjh7IN88US=>Mkm2V2FPT0WU
SW948NWjTTWxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDPRmsxUUN3ME20Ok41PDZ{IN88US=>MXTTRW5ITVJ?
NCI-H460MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3:yd2lEPTB;NE[uOVI{KM7:TR?=NX\hN5NOW0GQR1XS
CAS-1M3XmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{P5PGlEPTB;NE[uO|cxOSEQvF2=MkH1V2FPT0WU
TGBC11TKBM3zCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPuUXpKSzVyPUS3MlE4PzdizszNMWDTRW5ITVJ?
HD-MY-ZM4TJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4SxfGlEPTB;NEiuO|g3KM7:TR?=NUjTbFBLW0GQR1XS
NCI-H226MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWP1VYJEUUN3ME20PU44Pzh3IN88US=>M17NW3NCVkeHUh?=
PA-1NXvle2ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTR7LkizN|Uh|ryPNGLGeXlUSU6JRWK=
LB2518-MELNYjTZ3dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXtTWM2OD12OT64O|I{KM7:TR?=NHTiVXVUSU6JRWK=
A101DM{PEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TUU2lEPTB;NEmuPVQzPSEQvF2=MWrTRW5ITVJ?
NCI-H2087NGnFcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fMNmlEPTB;NEmuPVY5OiEQvF2=M2PwenNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. [1]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

In vitro kinase activity assays The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.

Cell Assay:

[1]

Cell lines NSCLC cells
Concentrations 0-10 μM
Incubation Time 1 hour
Method

1 × 104 NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 104 cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm.

Animal Study:

[1]

Animal Models Athymic NMRI-nu/nu female mice
Formulation In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80)
Dosages 20 mg/kg
Administration Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Li D, et al. Oncogene, 2008, 27(34), 4702-4711.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02501603 Recruiting Gastric Cancer|Gastroesophageal Junction Cancer Yonsei University July 2016 Phase 2
NCT02795156 Not yet recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boe  ...more SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer July 2016 Phase 2
NCT02780687 Recruiting Urologic Neoplasms Boehringer Ingelheim June 2016 Phase 2
NCT02183883 Not yet recruiting Non-small Cell Lung Cancer University College, London|Boehringer Ingelheim May 2016 Phase 2
NCT02716311 Not yet recruiting Non Small Cell Lung Cancer Intergroupe Francophone de Cancerologie Thoracique April 2016 Phase 2

view more

Chemical Information

Download Afatinib (BIBW2992) SDF
Molecular Weight (MW) 485.94
Formula

C24H25ClFN5O3

CAS No. 439081-18-2
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 97 mg/mL (199.61 mM)
Ethanol 15 mg/mL (30.86 mM)
Water <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 10mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide

Frequently Asked Questions

  • Question 1
    What’s the recommendation about reconstitution of the compound for in vivo animal study?

    Answer: For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Osimertinib (AZD9291)

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • Lapatinib

    Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • AG-1478 (Tyrphostin AG-1478)

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Recently Viewed Items

Tags: buy Afatinib (BIBW2992) | Afatinib (BIBW2992) supplier | purchase Afatinib (BIBW2992) | Afatinib (BIBW2992) cost | Afatinib (BIBW2992) manufacturer | order Afatinib (BIBW2992) | Afatinib (BIBW2992) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us